Merck & Co. enters its August 4 Q2 earnings call with Barclays lifting its target to $150 that same morning — the most bullish Street action yet in a month of relentless upward revisions.
The analyst tide has been nearly one-directional. Barclays raised its target from $140 to $150 on July 29, maintaining Overweight. That follows JP Morgan lifting to $140 from $135 on July 13, Wells Fargo raising to $150 from $145 on July 8, and Bank of America moving to $141 from $130 on June 30. Every major firm that has touched the name over the past month has moved targets higher. The lone holdout is Morgan Stanley at Equal-Weight with a $113 target — well below the consensus mean of $135.19 — making it the clearest voice of caution on the Street. The consensus implies roughly 2.5% further upside from Tuesday's $131.82 close, modest but positive, and the bull case centres on Keytruda's durability and pipeline depth, while bears focus on patent cliff risk and near-term competitive pressure in oncology.
The positioning picture is about as unencumbered as it gets for a large-cap pharmaceutical name. Short interest has collapsed 22% over the past week to just 1.0% of the free float — a rounding error for a stock of this size, and consistent with the retreat flagged in the previous note. Borrow availability is essentially unlimited, with no meaningful squeeze dynamic in play. Cost to borrow is a negligible 0.45%, slightly lower on the week. The ORTEX short score has drifted down to 29.9 from 32.2 two weeks ago, reflecting the continued unwind of the short position. None of this points to any technical complexity heading into the print — bears have already largely exited.
Options traders are equally calm. The put/call ratio at 0.78 is fractionally below its 20-day average of 0.80, with a z-score of -0.47 — close to neutral and well inside the 52-week range of 0.52 to 0.98. There is no elevated demand for downside protection ahead of earnings. The contrast with earlier in the cycle is notable: in mid-June the PCR was running near 0.98, close to the annual high. It has since unwound entirely, tracking the stock's recovery.
The stock added 4.4% on the week and 2.5% on the month to close at $131.82. That puts it meaningfully ahead of the peer group: JNJ gained 6.4% on the week, GSK added 7.2%, and BMY rose 4.4%, making this a broad pharma rally rather than an MRK-specific story. The dividend factor score ranks in the 96th percentile, EPS surprise in the 75th, and the short score rank at the 83rd — a reminder that the data composite has been pointing bullish for several weeks. The prior two earnings reactions were modest: a 1.1% gain the day after the April 30 Q1 print, and a 1.8% decline after the May 26 event, both with limited five-day follow-through. The bar heading into August 4 is higher than it has been.
The question now is whether Q2 revenues and any forward guidance on Keytruda's trajectory can justify the target-price clustering near $140–$150 that the Street has rapidly converged on.
See the live data behind this article on ORTEX.
Open MRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
